Pancreatic neuroendocrine tumors

Current Problems in Surgery

Volumn 50, Issue 11, 2013, Pages 509-545

  Krampitz, Geoffrey W ^a   Norton, Jeffrey A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CAPECITABINE; DIAZOXIDE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GLUCAGON; INSULIN; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DIET RESTRICTION; DIET THERAPY; DUODENOSTOMY; EDEMA; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; GENE; GLUCAGONOMA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULINOMA; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MEN1 GENE; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS RESECTION; PANCREATIC NEUROENDOCRINE TUMOR; SERODIAGNOSIS; SIDE EFFECT; SODIUM RETENTION; SOMATOSTATINOMA; SURGICAL APPROACH; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; ZOLLINGER ELLISON SYNDROME;

ANTINEOPLASTIC AGENTS, HORMONAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INCIDENCE; INSULINOMA; MALE; MUTATION; NEOPLASM STAGING; NESIDIOBLASTOSIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; ZOLLINGER-ELLISON SYNDROME;

EID: 84887253440     PISSN: 00113840     EISSN: 15356337     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2013.08.001     Document Type: Article

References (226)

1. Vortmeyer A.O., Huang S., Lubensky I., Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004, 89(4):1934-1938.
2. Rindi G., Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2 2011.
3. Halfdanarson T.R., Rubin J., Farnell M.B., Grant C.S., Petersen G.M. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008, 15(2):409-427.
4. Ellison T.A., Edil B.H. The current management of pancreatic neuroendocrine tumors. Adv Surg 2012, 46:283-296.
5. Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev 2011, 37(2):127-132.
6. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135(5):1469-1492.
7. Foreman K.E.R.P., Osipo C., Miele L. The Cancer Stem Cell Hypothesis. Stem Cells and Cancer 2009, 14-26. Springer, New York. B.R.G. TB (Ed.).
8. Jiao Y., Shi C., Edil B.H., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 4 2011, 331(6021):1199-1203.
9. Heaphy C.M., de Wilde R.F., Jiao Y., et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333(6041):425.
10. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12(2):133-143.
11. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
12. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645-648.
13. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730-737.
14. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401.
15. Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64(19):7011-7021.
16. Hemmati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003, 100(25):15178-15183.
17. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100(7):3983-3988.
18. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104(3):973-978.
19. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123):106-110.
20. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-1037.
21. Yang Z.F., Ho D.W., Ng M.N., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13(2):153-166.
22. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006, 103(30):11154-11159.
23. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25(12):1696-1708.
24. Gaur P., Sceusi E.L., Samuel S., et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011, 141(5):1728-1737.
25. Diehn M., Cho R.W., Clarke M.F. Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol 2009, 19(2):78-86.
26. Al-Hajj M., Becker M.W., Wicha M., Weissman I., Clarke M.F. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004, 14(1):43-47.
27. Costello R.T., Mallet F., Gaugler B., et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000, 60(16):4403-4411.
28. Gangemi R., Paleari L., Orengo A.M., et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem 2009, 16(14):1688-1703.
29. Ou Y., Guo X.L. Tumor stem cells and drug resistance. Sheng Li Ke Xue Jin Zhan 2007, 38(2):115-119.
30. Sabisz M., Skladanowski A. Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle 2009, 8(19):3208-3217.
31. Qin K., Jiang X., Zou Y., Wang J., Qin L., Zeng Y. Study on the proliferation and drug-resistance of human brain tumor stem-like cells. Cell Mol Neurobiol 2010, 30(6):955-960.
32. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284.
33. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002, 99(25):16220-16225.
34. Chao M.P., Alizadeh A.A., Tang C., et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011, 71(4):1374-1384.
35. Chao M.P., Alizadeh A.A., Tang C., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142(5):699-713.
36. Thompson N.W., Lloyd R.V., Nishiyama R.H., et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984, 8(4):561-574.
37. Langer P., Wild A., Hall A., Celik I., Rothmund M., Bartsch D.K. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours. Br J Surg 2003, 90(12):1599-1603.
38. Oberg K., Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005, 19(5):753-781.
39. Norton J.A. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994, 31(2):77-156.
40. Chandrasekharappa S.C., Guru S.C., Manickam P., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276(5311):404-407.
41. Lemmens I., Van de Ven W.J., Kas K., et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997, 6(7):1177-1183.
42. Marx S.J., Agarwal S.K., Heppner C., et al. The gene for multiple endocrine neoplasia type 1: recent findings. Bone 1999, 25(1):119-122.
43. Capurso G., Festa S., Valente R., et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 2012, 49(1):R37-R50.
44. Jensen R.T., Berna M.J., Bingham D.B., Norton J.A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008, 113(7 Suppl):1807-1843.
45. Norton J.A., Fang T.D., Jensen R.T. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw 2006, 4(2):148-153.
46. Wilder R.M.A.F., Power M.H., Robertson H.E. Carcinoma of islands of pancreas: hyperinsulinism and hypoglycemia. J Am Med Assoc 1927, 89:348-355.
47. Doherty G.M., Doppman J.L., Shawker T.H., et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991, 110(6):989-996. [discussion 996-987].
48. Dizon A.M., Kowalyk S., Hoogwerf B.J. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999, 106(3):307-310.
49. Marx S., Spiegel A.M., Skarulis M.C., Doppman J.L., Collins F.S., Liotta L.A. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998, 129(6):484-494.
50. Norton J.A., Doherty G.M., Fraker D.L. Surgery for Endocrine Tumors of the Pancreas 1993, Raven Press, New York. 2nd ed.
51. Norton J.A. Pancreatic Islet Cell Tumors Excluding Gastrinomas 1998, Mosby, St. Louis.
52. Sheppard B.C., Norton J.A., Doppman J.L., Maton P.N., Gardner J.D., Jensen R.T. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989, 106(6):1108-1117. [discussion 1117-1108].
53. Anlauf M., Schlenger R., Perren A., et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006, 30(5):560-574.
54. Anlauf M., Bauersfeld J., Raffel A., et al. Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol 2009, 33(3):339-346.
55. Peplinski G.R., Norton J.A. Gastrointestinal endocrine cancers and nodal metastasis: biologic significance and therapeutic implications. Surg Oncol Clin N Am 1996, 5(1):159-171.
56. Grant C.S., van Heerden J., Charboneau J.W., James E.M., Reading C.C. Insulinoma. The value of intraoperative ultrasonography. Arch Surg 1988, 123(7):843-848.
57. Hiramoto J.S., Feldstein V.A., LaBerge J.M., Norton J.A. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 2001, 136(9):1020-1025. [discussion 1025-6].
58. Service F.J., McMahon M.M., O'Brien P.C., Ballard D.J. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991, 66(7):711-719.
59. Gorden P., Skarulis M.C., Roach P., et al. Plasma proinsulin-like component in insulinoma: a 25-year experience. J Clin Endocrinol Metab 1995, 80(10):2884-2887.
60. Grunberger G., Weiner J.L., Silverman R., Taylor S., Gorden P. Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. Ann Intern Med 1988, 108(2):252-257.
61. Basu A., Sheehan M.T., Thompson G.B., Service F.J. Insulinoma in chronic renal failure: a case report. J Clin Endocrinol Metab 2002, 87(11):4889-4891.
62. Thornton P.S., Alter C.A., Katz L.E., Baker L., Stanley C.A. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993, 123(4):637-643.
63. Glaser B., Hirsch H.J., Landau H. Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 1993, 123(4):644-650.
64. Service G.J., Thompson G.B., Service F.J., Andrews J.C., Collazo-Clavell M.L., Lloyd R.V. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005, 353(3):249-254.
65. Goudswaard W.B., Houthoff H.J., Koudstaal J., Zwierstra R.P. Nesidioblastosis and endocrine hyperplasia of the pancreas: a secondary phenomenon. Hum Pathol 1986, 17(1):46-54.
66. Grant C.S. Insulinoma. Surg Oncol Clin N Am 1998, 7(4):819-844.
67. Fraker D.L., Norton J.A. Localization and resection of insulinomas and gastrinomas. J Am Med Assoc 1988, 259(24):3601-3605.
68. Doppman J.L., Chang R., Fraker D.L., et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995, 123(4):269-273.
69. Vinik A.I., Delbridge L., Moattari R., Cho K., Thompson N. Transhepatic portal vein catheterization for localization of insulinomas: a ten-year experience. Surgery 1991, 109(1):1-11. [discussion 111].
70. Gianello P., Gigot J.F., Berthet F., et al. Pre- and intraoperative localization of insulinomas: report of 22 observations. World J Surg 1988, 12(3):389-397.
71. Rodallec M., Vilgrain V., Zins M., Couvelard A., Ruszniewski P., Menu Y. Helical CT of pancreatic endocrine tumors. J Comput Assist Tomogr 2002, 26(5):728-733.
72. Fidler J.L., Fletcher J.G., Reading C.C., et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. Am J Roentgenol 2003, 181(3):775-780.
73. Gouya H., Vignaux O., Augui J., et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 2003, 181(4):987-992.
74. Liu Y., Song Q., Jin H.T., Lin X.Z., Chen K.M. The value of multidetector-row CT in the preoperative detection of pancreatic insulinomas. Radiol Med 2009, 114(8):1232-1238.
75. Lin X.Z., Wu Z.Y., Tao R., et al. Dual energy spectral CT imaging of insulinoma-value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol 2012, 81(10):2487-2494.
76. Placzkowski K.A., Vella A., Thompson G.B., et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 2009, 94(4):1069-1073.
77. Paul T.V., Jacob J.J., Vasan S.K., et al. Management of insulinomas: analysis from a tertiary care referral center in India. World J Surg 2008, 32(4):576-582.
78. Ravi K., Britton B.J. Surgical approach to insulinomas: are pre-operative localisation tests necessary?. Ann R Coll Surg Engl 2007, 89(3):212-217.
79. Sotoudehmanesh R., Hedayat A., Shirazian N., et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 2007, 31(3):238-241.
80. Boukhman M.P., Karam J.M., Shaver J., Siperstein A.E., DeLorimier A.A., Clark O.H. Localization of insulinomas. Arch Surg 1999, 134(8):818-822. [discussion 822-813].
81. Gauger P.G., Scheiman J.M., Wamsteker E.J., Richards M.L., Doherty G.M., Thompson N.W. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003, 90(6):748-754.
82. Kann P.H. Endoscopic ultrasound imaging in neuroendocrine pancreatic tumors. A critical analysis. Med Klin (Munich) 2006, 101(7):546-551.
83. Rosch T., Lightdale C.J., Botet J.F., et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992, 326(26):1721-1726.
84. Zimmer T., Scherubl H., Faiss S., Stolzel U., Riecken E.O., Wiedenmann B. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000, 62(suppl 1):45-50.
85. Anderson M.A., Carpenter S., Thompson N.W., Nostrant T.T., Elta G.H., Scheiman J.M. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000, 95(9):2271-2277.
86. Ardengh J.C., Rosenbaum P., Ganc A.J., et al. Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointest Endosc 2000, 51(5):552-555.
87. Patel K.K., Kim M.K. Neuroendocrine tumors of the pancreas: endoscopic diagnosis. Curr Opin Gastroenterol 2008, 24(5):638-642.
88. Richards M.L., Gauger P.G., Thompson N.W., Kloos R.G., Giordano T.J. Pitfalls in the surgical treatment of insulinoma. Surgery 2002, 132(6):1040-1049. [discussion 1049].
89. Kaplan E.L., Rubenstein A.H., Evans R., Lee C.H., Klementschitsch P. Calcium infusion: a new provocative test for insulinomas. Ann Surg 1979, 190(4):501-507.
90. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
91. Wollheim C.B., Sharp G.W. Regulation of insulin release by calcium. Physiol Rev Oct 1981, 61(4):914-973.
92. Kato M., Doi R., Imamura M., Furutani M., Hosotani R., Shimada Y. Calcium-evoked insulin release from insulinoma cells is mediated via calcium-sensing receptor. Surgery 1997, 122(6):1203-1211.
93. Brown C.K., Bartlett D.L., Doppman J.L., et al. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery 1997, 122(6):1189-1193. [discussion 1193-1184].
94. Cohen M.S., Picus D., Lairmore T.C., Strasberg S.M., Doherty G.M., Norton J.A. Prospective study of provocative angiograms to localize functional islet cell tumors of the pancreas. Surgery 1997, 122(6):1091-1100.
95. Noldge G., Weber M.A., Ritzel R.A., Werner M.J., Kauczor H.U., Grenacher L. Invasive diagnostic procedures for insulinomas of the pancreas. Radiology 2009, 49(3):224-232.
96. Morganstein D.L., Lewis D.H., Jackson J., et al. The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol 2009, 19(10):2467-2473.
97. Machado M.C., da Cunha J.E., Jukemura J., et al. Insulinoma: diagnostic strategies and surgical treatment. A 22-year experience. Hepatogastroenterology 2001, 48(39):854-858.
98. Brandle M., Pfammatter T., Spinas G.A., Lehmann R., Schmid C. Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol (Oxf) 2001, 55(3):357-362.
99. Chavan A., Kirchhoff T.D., Brabant G., Scheumann G.F., Wagner S., Galanski M. Role of the intra-arterial calcium stimulation test in the preoperative localization of insulinomas. Eur Radiol 2000, 10(10):1582-1586.
100. Geoghegan J.G., Jackson J.E., Lewis M.P., et al. Localization and surgical management of insulinoma. Br J Surg 1994, 81(7):1025-1028.
101. Norton J.A., Cromack D.T., Shawker T.H., et al. Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg 1988, 207(2):160-168.
102. de Herder W.W., Niederle B., Scoazec J.Y., et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006, 84(3):183-188.
103. Fajans S.S., Vinik A.I. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 1989, 18(1):45-74.
104. Yao J.C., Eisner M.P., Leary C., et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007, 14(12):3492-3500.
105. Gill G.V., Rauf O., MacFarlane I.A. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997, 73(864):640-641.
106. Burch P.G., McLeskey C.H. Anesthesia for patients with insulinoma treatment with oral diazoxide. Anesthesiology 1981, 55(4):472-475.
107. Gorden P., Comi R.J., Maton P.N., Go V.L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989, 110(1):35-50.
108. Arnold R., Wied M., Behr T.H. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002, 3(6):643-656.
109. Mathur A., Gorden P., Libutti S.K. Insulinoma. Surg Clin North Am 2009, 89(5):1105-1121.
110. Bertherat J., Tenenbaum F., Perlemoine K., et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003, 88(11):5353-5360.
111. Korner M., Christ E., Wild D., Reubi J.C. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne) 2012, 3:158.
112. Norton J.A., Sigel B., Baker A.R., et al. Localization of an occult insulinoma by intraoperative ultrasonography. Surgery 1985, 97(3):381-384.
113. Demeure M.J., Klonoff D.C., Karam J.H., Duh Q.Y., Clark O.H. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991, 110(6):998-1004. [discussion 1004-1005].
114. O'Riordain D.S., O'Brien T., van Heerden J.A., Service F.J., Grant C.S. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994, 18(4):488-493. [discussion 493-484].
115. Carneiro D.M., Levi J.U., Irvin 3rd Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery 2002, 132(6):937-942. [discussion 942-933].
116. Proye C., Pattou F., Carnaille B., Lefebvre J., Decoulx M., d'Herbomez M. Intraoperative insulin measurement during surgical management of insulinomas. World J Surg 1998, 22(12):1218-1224.
117. Veldhuis J.D., Norton J.A., Wells Jr, Vinik A.I., Perry R.R. Surgical versus medical management of multiple endocrine neoplasia (MEN) type I. J Clin Endocrinol Metab 1997, 82(2):357-364.
118. Pierce R.A., Spitler J.A., Hawkins W.G., et al. Outcomes analysis of laparoscopic resection of pancreatic neoplasms. Surg Endosc 2007, 21(4):579-586.
119. Toniato A., Meduri F., Foletto M., Avogaro A., Pelizzo M. Laparoscopic treatment of benign insulinomas localized in the body and tail of the pancreas: a single-center experience. World J Surg 2006, 30(10):1916-1919. [discussion 1920-1911].
120. Zollinger R.M.E.E. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955, 142(4):709-723. ([discussion, 724-708]).
121. Grobmyer S.R., Hochwald S.N. Reoperative surgery for the Zollinger-Ellison syndrome. Adv Surg 2010, 44:327-346.
122. Eriksson B., Oberg K., Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 1989, 28(3):373-377.
123. Gibril F., Jensen R.T. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004, 6(6):454-463.
124. Stabile B.E., Morrow D.J., Passaro Jr The gastrinoma triangle: operative implications. Am J Surg 1984, 147(1):25-31.
125. Cisco R.M., Norton J.A. Surgery for gastrinoma. Adv Surg. 2007, 41:165-176.
126. Behe M., Gotthardt M., Behr T.M. Imaging of gastrinomas by nuclear medicine methods. Wien Klin Wochenschr 2007, 119(19-20):593-596.
127. Gibril F., Jensen R.T. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005, 7(2):114-121.
128. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.J., Gibril F., Jensen R.T. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 2003, 237(5):650-657. [discussion 657-659].
129. Norton J.A. Advances in the management of Zollinger-Ellison syndrome. Adv Surg 1994, 27:129-159.
130. Wolfe M.M., Alexander R.W., McGuigan J.E. Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery. N Engl J Med 1982, 306(25):1533-1536.
131. Perrier N.D., Batts K.P., Thompson G.B., Grant C.S., Plummer T.B. An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas? Mayo Clinic Pancreatic Surgery Group. Surgery 1995, 118(6):957-965. [discussion 965-956].
132. Herrmann M.E., Ciesla M.C., Chejfec G., DeJong S.A., Yong S.L. Primary nodal gastrinomas. Arch Pathol Lab Med 2000, 124(6):832-835.
133. Sutliff V.E., Doppman J.L., Gibril F., et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997, 15(6):2420-2431.
134. Norton J.A. Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005, 19(4):577-583.
135. Roland C.L., Bian A., Mansour J.C., et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2011.
136. Stabile B.E., Passaro Jr Benign and malignant gastrinoma. Am J Surg 1985, 149(1):144-150.
137. Roland C.L., Bian A., Mansour J.C., et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012, 105(6):595-600.
138. Pape U.F., Jann H., Muller-Nordhorn J., et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008, 113(2):256-265.
139. Nikfarjam M., Warshaw A.L., Axelrod L., et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008, 247(1):165-172.
140. Kazanjian K.K., Reber H.A., Hines O.J. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006, 141(8):765-769. [discussion 769-770].
141. Hochwald S.N., Zee S., Conlon K.C., et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002, 20(11):2633-2642.
142. Fendrich V., Langer P., Celik I., et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006, 244(6):845-851. [discussion 852-843].
143. Ellison E.C., Sparks J., Verducci J.S., et al. 50-Year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg 2006, 202(6):897-905.
144. Ekeblad S., Skogseid B., Dunder K., Oberg K., Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008, 14(23):7798-7803.
145. DiNorcia J., Lee M.K., Reavey P.L., et al. One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg 2010, 14(10):1536-1546.
146. Bilimoria K.Y., Talamonti M.S., Tomlinson J.S., et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008, 247(3):490-500.
147. Chu Q.D., Hill H.C., Douglass Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002, 9(9):855-862.
148. Jensen R.T., Niederle B., Mitry E., et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006, 84(3):173-182.
149. Schurr P.G., Strate T., Rese K., et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007, 245(2):273-281.
150. Fischer L., Kleeff J., Esposito I., et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008, 95(5):627-635.
151. Weber H.C., Venzon D.J., Lin J.T., et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995, 108(6):1637-1649.
152. Yu F., Venzon D.J., Serrano J., et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999, 17(2):615-630.
153. Tomassetti P., Campana D., Piscitelli L., et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005, 16(11):1806-1810.
154. Bettini R., Boninsegna L., Mantovani W., et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008, 19(5):903-908.
155. Boninsegna L., Panzuto F., Partelli S., et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012, 48(11):1608-1615.
156. Krampitz G.W., Norton J.A., Poultsides G.A., Visser B.C., Sun L., Jensen R.T. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg 2012, 147(9):820-827.
157. Gibril F., Schumann M., Pace A., Jensen R.T. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004, 83(1):43-83.
158. Norton J.A., Cornelius M.J., Doppman J.L., Maton P.N., Gardner J.D., Jensen R.T. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987, 102(6):958-966.
159. Lewis R.B., Lattin Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 2010, 30(6):1445-1464.
160. Poultsides G.A., Huang L.C., Chen Y., et al. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol 2012, 19(7):2295-2303.
161. Wank S.A., Doppman J.L., Miller D.L., et al. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987, 92(4):905-912.
162. Horton K.M., Hruban R.H., Yeo C., Fishman E.K. Multi-detector row CT of pancreatic islet cell tumors. Radiographics 2006, 26(2):453-464.
163. Thoeni R.F., Mueller-Lisse U.G., Chan R., Do N.K., Shyn P.B. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000, 214(2):483-490.
164. Ichikawa T., Peterson M.S., Federle M.P., et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000, 216(1):163-171.
165. Alexander H.R., Fraker D.L., Norton J.A., et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998, 228(2):228-238.
166. Gibril F., Reynolds J.C., Doppman J.L., et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996, 125(1):26-34.
167. Schillaci O., Spanu A., Scopinaro F., et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003, 44(3):359-368.
168. Modlin I.M., Tang L.H. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997, 112(2):583-590.
169. Schillaci O., Corleto V.D., Annibale B., Scopinaro F., Delle Fave G. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999, 31(suppl 2):S186-S189.
170. 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003, 59(5):565-573.
171. Norton J.A., Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004, 240(5):757-773.
172. Imamura M., Komoto I., Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg 2006, 30(1):1-11.
173. Meko J.B., Doherty G.M., Siegel B.A., Norton J.A. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Surgery 1996, 120(6):975-983. [discussion 983-974].
174. Rufini V., Calcagni M.L., Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 2006, 36(3):228-247.
175. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48(4):508-518.
176. McLean A. Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging 2004, 4(2):84-91.
177. Imaoka H., Yamao K., Bhatia V., et al. Rare pancreatic neoplasms: the utility of endoscopic ultrasound-guided fine-needle aspiration-a large single center study. J Gastroenterol 2009, 44(2):146-153.
178. Norton J.A. Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum. Ital J Gastroenterol Hepatol 1999, 31(Suppl 2):S195-S197.
179. von Eyben F.E., Grodum E., Gjessing H.J., Hagen C., Nielsen H. Metabolic remission with octreotide in patients with insulinoma. J Intern Med 1994, 235(3):245-248.
180. Norton J.A., Fraker D.L., Alexander H.R., Jensen R.T. Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. Ann Surg 2012, 256(3):509-517.
181. Thompson N.W., Vinik A.I., Eckhauser F.E. Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg 1989, 209(4):396-404.
182. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999, 341(9):635-644.
183. Howard T.J., Zinner M.J., Stabile B.E., Passaro Jr Gastrinoma excision for cure. A prospective analysis. Ann Surg 1990, 211(1):9-14.
184. Wolfe M.M., Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000, 118(2 suppl 1). (S9-31).
185. Maton P.N., Vinayek R., Frucht H., et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989, 97(4):827-836.
186. Norton J.A. Gastrinoma: advances in localization and treatment. Surg Oncol Clin N Am 1998, 7(4):845-861.
187. Maton P.N., Frucht H., Vinayek R., Wank S.A., Gardner J.D., Jensen R.T. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988, 94(2):294-299.
188. Fox P.S., Hofmann J.W., Decosse J.J., Wilson S.D. The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors. Ann Surg 1974, 180(4):558-566.
189. Zollinger R.M., Ellison E.C., O'Dorisio T.M., Sparks J. Thirty years' experience with gastrinoma. World J Surg 1984, 8(4):427-435.
190. Li M.L., Norton J.A. Gastrinoma. Curr Treat Options Oncol 2001, 2(4):337-346.
191. Meko J.B., Norton J.A. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995, 46:395-411.
192. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006, 244(3):410-419.
193. Frucht H., Norton J.A., London J.F., et al. Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. Gastroenterology 1990, 99(6):1622-1627.
194. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86(12):5658-5671.
195. Norton J.A., Harris E.J., Chen Y., et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 2011, 146(6):724-732.
196. Ehehalt F., Saeger H.D., Schmidt C.M., Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009, 14(5):456-467.
197. Jensen R.T. Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999, 10(Suppl 4):170-176.
198. Baudin E., Gigliotti A., Ducreux M., et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998, 78(8):1102-1107.
199. Pirker R.A., Pont J., Pohnl R., Schutz W., Griesmacher A., Muller M.M. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med 1998, 36(11):837-840.
200. Nobels F.R., Kwekkeboom D.J., Bouillon R., Lamberts S.W. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998, 28(6):431-440.
201. van Eijck C.H., Lamberts S.W., Lemaire L.C., et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996, 224(2):119-124.
202. Batcher E., Madaj P., Gianoukakis A.G. Pancreatic neuroendocrine tumors. Endocr Res 2011, 36(1):35-43.
203. Bornman P.C., Beckingham I.J. ABC of diseases of liver, pancreas, and biliary system. Pancreatic tumours. Br Med J 2001, 322(7288):721-723.
204. Chastain M.A. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001, 321(5):306-320.
205. McGevna L., Tavakkol Z. Images in clinical medicine. Necrolytic migratory erythema. N Engl J Med 2010, 362(1):e1.
206. Afsharfard A., Atqiaee K., Lotfollahzadeh S., Alborzi M., Derakhshanfar A. Necrolytic migratory erythema as the first manifestation of glucagonoma. Case Rep Surg 2012, 974210.
207. Laburthe M., Couvineau A., Marie J.C. VPAC receptors for VIP and PACAP. Receptors Channels 2002, 8(3-4):137-153.
208. Laburthe M., Couvineau A. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept 2002, 108(2-3):165-173.
209. Greenup R., Wang T.S., Evans D.B. Evaluation of "Other" neuroendocrine tumors of the pancreas. The Handbook of Endocrine Surgery 2012, 397-402. World Scientific Publishing, Singapore. R.S. Sippel, H. Chen (Eds.).
210. Thompson N.W. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998, 243(6):495-500.
211. Vinik A.I., Strodel W.E., Eckhauser F.E., Moattari A.R., Lloyd Lloyd R. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 1987, 14(3):263-281.
212. Verner J.V., Morrison A.B. Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 1974, 133(3):492-499.
213. Capella C., Polak J.M., Buffa R., et al. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer 1983, 52(10):1860-1874.
214. Caplan R.H., Koob L., Abellera R.M., Pagliara A.S., Kovacs K., Randall R.V. Cure of acromegaly by operative removal of an islet cell tumor of the pancreas. Am J Med 1978, 64(5):874-882.
215. Bresler L., Boissel P., Conroy T., Grosdidier J. Pancreatic islet cell carcinoma with hypercalcemia: complete remission 5 years after surgical excision and chemotherapy. Am J Gastroenterol 1991, 86(5):635-638.
216. Strosberg J.R., Fine R.L., Choi J., et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117(2):268-275.
217. Jensen R.T., Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011, 364(6):564-565.
218. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):514-523.
219. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):501-513.
220. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010, 37(6):594-618.
221. Moertel C.G., Hanley J.A., Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980, 303(21):1189-1194.
222. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326(8):519-523.
223. Yao J.C., Lombard-Bohas C., Baudin E., et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28(1):69-76.
224. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26(26):4311-4318.
225. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24(1):25-35.
226. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26(20):3403-3410.